Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectable PRF in Management of Temporomandibular Joint Internal Derangement
NCT07789860Phase 3Completed
- Sponsor
- Suez Canal University
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 3, randomised trial of platelet rich fibrin in temporomandibular joint internal derangement (TMJID) (2 arms), sponsored by Suez Canal University. Primary endpoints: Maximum mouth opening at 6 months and Temporomandibular joint pain at 6 months. Started Sep 2023; status: completed.
02
Drugs
platelet rich fibrin
03
Conditions
temporomandibular joint internal derangement (TMJID)
Beyond the preview
Go deeper on NCT07789860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789860.